Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $73.81 USD
Change Today -0.27 / -0.36%
Volume 4.6M
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

medtronic plc (MDT) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/25/15 - $79.50
52 Week Low
10/15/14 - $59.83
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDTRONIC PLC (MDT)

medtronic plc (MDT) Details

Medtronic plc manufactures and sells device-based medical therapies worldwide. The company’s Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators, implantable cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, and peripheral vascular intervention products. Its Minimally Invasive Therapies Group segment provides gastrointestinal diagnostics, ablation, and interventional lung solutions; stapling, vessel sealing, and other surgical instruments; sutures; electrosurgery products; hernia mechanical devices; mesh implants; products for patient monitoring and recovery, such as ventilators, capnography, and other airway products; sensors; monitors; compression and dialysis products; enteral feeding; wound care; and medical surgical products comprising operating room supply products, electrodes, needles, syringes, and sharps disposals. The company’s Restorative Therapies Group segment offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, and throat; systems that incorporate advanced energy surgical instruments; and image-guided surgery and intra-operative imaging systems. Its Diabetes Group segment provides insulin pumps; continuous glucose monitoring systems; insulin pump consumables; and Web-based therapy management software solutions. It serves hospitals, physicians, clinicians, and patients. Medtronic plc was founded in 1949 and is headquartered in Dublin, Ireland.

92,500 Employees
Last Reported Date: 06/23/15
Founded in 1949

medtronic plc (MDT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $774.9K
Executive Vice President and Group President ...
Total Annual Compensation: $724.9K
Chief Human Resources Officer and Senior Vice...
Total Annual Compensation: $781.7K
Compensation as of Fiscal Year 2014.

medtronic plc (MDT) Key Developments

Medtronic plc Announces the Twelve-Month Results of the Veclose Pivotal Study

Medtronic plc announced the twelve-month results of the VeClose pivotal study, which demonstrated the safety and effectiveness of the VenaSeal(TM) closure system for the treatment of incompetent greater saphenous veins with a 96.8% closure rate. The VenaSeal closure system is a unique, minimally invasive, non-tumescent, non-thermal and non-sclerosant procedure that uses an advanced medical adhesive to close the diseased vein in patients with symptomatic venous reflux disease. Unlike other treatments, the VenaSeal closure system does not require tumescent anesthesia, allowing patients to return to their normal activities following the procedure. The VenaSeal procedure also eliminates the risk of nerve or other heat-related injury associated with thermal-based procedures, and may reduce the need for compression stockings post-procedure. The 12 month results of the VeClose study demonstrated outcomes for the VenaSeal closure system comparable with the closure rates associated with the ClosureFastTM catheter and demonstrated non-inferiority of the VenaSeal closure system.

U.S. Food and Drug Administration Approves Commercial Launch of the Advisa SR MRI(TM) SureScan(R) Single-Chamber Pacemaker with the 5076 MRI Lead

Medtronic plc announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of the Advisa SR MRI(TM) SureScan(R) single-chamber pacemaker with the 5076 MRI lead, which allows for magnetic resonance imaging (MRI) scans positioned on any region of the body without restrictions. The new system includes the Advisa SR MRI pacemaker and a SureScan lead, which must be used together to be considered MR-conditional. In addition to delivering single chamber pacing with the same SureScan(R) technology used in other Medtronic cardiac devices, the new Advisa SR MRI(TM) pacemaker has improved diagnostic information and storage, and a 35% improvement in battery longevity (when compared to the Adapta(R) single chamber pacing system). The Advisa single chamber pacemaker is the latest addition to a growing number of Medtronic devices that are designed for MRI access including the Advisa DR MRI(R) and Revo MRI(R) dual chamber SureScan pacing systems, the Reveal LINQ(R)Insertable Cardiac Monitoring (ICM) system, SureScan neurostimulation systems and the SynchroMed(R) II programmable drug infusion system which are available worldwide.

Medtronic plc Announces Management Changes

Medtronic plc announced that it has named Geoff Martha as Executive Vice President and President, Medtronic Restorative Therapies Group (RTG), effective immediately. Martha will replace Christopher J. O'Connell, who was selected to become Chief Executive Officer of a public company. Martha joined Medtronic in 2011 and currently serves as Sr. Vice President of Corporate Strategy & Business Development, Global Communications and Medtronic Philanthropy. He also serves as the Chief Integration Officer for the Covidien integration. In these roles, he has a broad understanding of Medtronic strategies and operations around the world. Prior to joining Medtronic, Martha served as managing director of Business Development at GE Healthcare, where he was responsible for global business development efforts, including acquisitions, divestitures, joint ventures and equity investments.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:US $73.81 USD -0.27

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $68.21 USD -0.30
Amgen Inc $153.26 USD -1.73
Bristol-Myers Squibb Co $67.48 USD -0.19
Eli Lilly & Co $86.14 USD +1.29
GlaxoSmithKline PLC 1,348 GBp -7.50
View Industry Companies

Industry Analysis


Industry Average

Valuation MDT Industry Range
Price/Earnings 30.6x
Price/Sales 5.2x
Price/Book 2.0x
Price/Cash Flow 30.7x
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at